These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 34666510)

  • 1. Factors Associated With Initial Treatment Choice, Engagement, and Discontinuation for Patients With Opioid Use Disorder.
    Mutter R; Spencer D; McPheeters J
    Psychiatr Serv; 2022 Jun; 73(6):604-612. PubMed ID: 34666510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.
    Samples H; Williams AR; Crystal S; Olfson M
    J Subst Abuse Treat; 2022 Aug; 139():108774. PubMed ID: 35337716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.
    Anderson KE; Saloner B; Eckstein J; Chaisson CE; Scholle SH; Niles L; Dy S; Alexander GC
    Med Care; 2021 May; 59(5):393-401. PubMed ID: 33734194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.
    Samples H; Williams AR; Olfson M; Crystal S
    J Subst Abuse Treat; 2018 Dec; 95():9-17. PubMed ID: 30352671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
    Meinhofer A; Williams AR; Johnson P; Schackman BR; Bao Y
    J Subst Abuse Treat; 2019 Oct; 105():37-43. PubMed ID: 31443889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts.
    Hasan MM; Noor-E-Alam M; Mohite P; Islam MS; Modestino AS; Peckham AM; Young LD; Young GJ
    J Subst Abuse Treat; 2021 Dec; 131():108416. PubMed ID: 34098294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
    Finlay AK; Harris AH; Rosenthal J; Blue-Howells J; Clark S; McGuire J; Timko C; Frayne SM; Smelson D; Oliva E; Binswanger I
    Drug Alcohol Depend; 2016 Mar; 160():222-6. PubMed ID: 26832998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder.
    Shcherbakova N; Tereso G; Spain J; Roose RJ
    Ann Pharmacother; 2018 May; 52(5):405-414. PubMed ID: 29302989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
    Williams AR; Samples H; Crystal S; Olfson M
    Am J Psychiatry; 2020 Feb; 177(2):117-124. PubMed ID: 31786933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
    Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
    J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Year Retention in Buprenorphine Treatment for Opioid Use Disorder Among Privately Insured Adults.
    Manhapra A; Agbese E; Leslie DL; Rosenheck RA
    Psychiatr Serv; 2018 Jul; 69(7):768-776. PubMed ID: 29656707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder.
    Varisco T; Shen C; Thornton D
    J Subst Abuse Treat; 2020 Oct; 117():108073. PubMed ID: 32811630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
    Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
    Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D.
    Strickland JC; Huhn AS; Bergeria CL; Strain EC; Dunn KE
    J Addict Med; 2021 Jul-Aug 01; 15(4):325-333. PubMed ID: 33156180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indication-Specific Opioid Prescribing for US Patients With Medicaid or Private Insurance, 2017.
    Mikosz CA; Zhang K; Haegerich T; Xu L; Losby JL; Greenspan A; Baldwin G; Dowell D
    JAMA Netw Open; 2020 May; 3(5):e204514. PubMed ID: 32391892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mental health conditions and the risk of chronic opioid therapy among patients with rheumatoid arthritis: a retrospective veterans affairs cohort study.
    Liberman JS; D'Agostino McGowan L; Greevy RA; Morrow JA; Griffin MR; Roumie CL; Grijalva CG
    Clin Rheumatol; 2020 Jun; 39(6):1793-1802. PubMed ID: 32036583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization.
    Lo-Ciganic WH; Gellad WF; Gordon AJ; Cochran G; Zemaitis MA; Cathers T; Kelley D; Donohue JM
    Addiction; 2016 May; 111(5):892-902. PubMed ID: 26662858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.